Oasmia Pharmaceutical is a Swedish speciality pharma company focusing on its proprietary XR-17 technology platform to develop novel formulations of well-established cytostatic oncology treatments for human and animal health. Key assets include Apealea (partnered with Elevar), docetaxel micellar and Cantrixil.
Oasmia is focused on developing improved formulations of well-established cancer drugs through the application of its proprietary XR-17 platform. This solubility enhancing technology has received validation though a global partnership deal for lead asset Apealea (Cremophor-free paclitaxel) with Elevar Therapeutics across a variety of cancers. Apealea is approved in Europe for second-line ovarian cancer and Elevar is required to complete two new studies before an NDA filing in the US. Oasmia is working on additional nanoparticle formulations, including docetaxel micellar (Phase Ib prostate cancer). Recently in-licensed asset Cantrixil will start Phase II development in ovarian cancer in 2022. Oasmia’s animal health pipeline has two clinical stage assets, Paccal Vet and Doxophos Vet. At 31 December 2020, Oasmia had net cash of SEK287.4m. Our forecasts are under review.
Despite a slew of novel cancer drug treatments transforming care for many oncology indications, established chemotherapy regimens remain a cornerstone of treatment. Oasmia’s XR-17 technology is applicable to any solubility limited drug, which includes 10–15 different cytostatic agents, and can potentially provide an improved formulation and profile.